| abstract |
The invention relates to spirocyclic compounds, which are tryptophan hydroxylase (TPH) inhibitors, in particular Isoform 1 (TPH1), which are suitable for treating diseases or disorders associated with peripheral serotonin, including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory , metabolic diseases, as well as diseases associated with low bone mass, and serotonin syndrome and cancer. Useful spirocyclic compounds are represented by formula I |